Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4683 Target Snapshot

Prolyl endopeptidase FAP · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
819Compounds
124Assays
5Approved Drugs
937.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Prolyl endopeptidase FAP shows clinical signal disease relevance led by colorectal cancer. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q12884. Start with colorectal cancer, then reuse UniProt Q12884 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with colorectal cancer, then reuse UniProt Q12884 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
colorectal cancer

Prolyl endopeptidase FAP shows clinical signal disease relevance led by colorectal cancer. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with colorectal cancer because it currently carries clinical signal support. Linked drugs include F19 131I. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prolyl endopeptidase FAP as ChEMBL target CHEMBL4683, mapped to UniProt Q12884. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prolyl endopeptidase FAP
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4683
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q12884
Prolyl endopeptidase FAP
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Prolyl endopeptidase FAP is the right protein anchor across sources, using UniProt Q12884 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why colorectal cancer is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameProlyl endopeptidase FAP
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ12884
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProlyl endopeptidase FAP
UniProt AccessionQ12884
Component TypeProtein
Sequence Length760 aa

Prolyl endopeptidase FAP

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Prolyl endopeptidase FAP, mapped to UniProt Q12884. Sequence length is 760 aa.

Mapped IDQ12884
Review nameProlyl endopeptidase FAP
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Prolyl endopeptidase FAP shows clinical signal disease relevance led by colorectal cancer. 4 more disease programs remain visible in the same review block.

Clinical signal Phase I
colorectal cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugF19 131I
Clinical signal Phase I
metastatic melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugSIMLUKAFUSP ALFA
Clinical signal Phase I
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugSIMLUKAFUSP ALFA
Clinical signal Phase I
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugSIBROTUZUMAB
Clinical signal Phase I
renal cell carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugSIMLUKAFUSP ALFA
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with colorectal cancer because it currently carries clinical signal support. Linked drugs include F19 131I. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecolorectal cancer
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
3
Phase III
Assay Mix

Activity Type Distribution

IC50859.0
KI77.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4877950 10.05 IC50 0.089 Preclinical
CHEMBL4878759 9.89 IC50 0.13 Preclinical
CHEMBL4864809 9.74 IC50 0.18 Preclinical
CHEMBL4853661 9.72 IC50 0.19 Preclinical
CHEMBL5569730 9.68 IC50 0.21 Preclinical
CHEMBL4850601 9.66 IC50 0.22 Preclinical
CHEMBL4876026 9.51 IC50 0.31 Preclinical
CHEMBL4868869 9.49 IC50 0.32 Preclinical
CHEMBL5566777 9.49 IC50 0.32 Preclinical
CHEMBL4850484 9.48 IC50 0.33 Preclinical
Distribution

pChEMBL Value Distribution

58
5.0
42
5.5
40
6.0
35
6.5
52
7.0
47
7.5
28
8.0
15
8.5
20
9.0
6
9.5
pChEMBL
Approved Drugs

Approved Drugs

LINAGLIPTIN
CHEMBL237500
Approved 2011
Properties Compare Identifier
Assay Landscape

Assay Landscape

125
Total Assays
402
Tested Compounds
3
Assay Types
Binding — 87 assays, 402 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 67 275 6.1
cell-based format 16 77 7.9
assay format 4 50 5.8
ADME — 37 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 34 0 —
cell-based format 2 0 —
assay format 1 0 —
Functional — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 1 7.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine